Travere Therapeutics Q2 FY26 earnings call TVTX

Travere reported record FILSPARI demand in Q2 FY26, with over 2,000 new patient start forms across IgA nephropathy and FSGS, driving U.S. net product sales of $141.1 million, a 96% year-over-year increase. The FSGS launch, the first quarter with commercial availability for this indication, exceeded high expectations with rapid early adoption. Demand for IgA nephropathy also grew quarter-over-quarter, reinforcing FILSPARI's established positioning despite new market entrants. The company noted a broad prescriber base for FSGS, with most physicians initially prescribing for a single patient, indicating early market uptake and potential for deeper prescribing.

The company continues to advance its intellectual property strategy for sparsentan. During the quarter, the USPTO issued a Notice of Allowance for a U.S. patent application related to certain methods of using sparsentan in IgA nephropathy, which is expected to provide U.S. patent coverage upon issuance. Travere is also pursuing additional patent coverage for sparsentan, including a pending U.S. application for methods of use in FSGS.

Pegtibatinase, a potential disease-modifying therapy for classical homocystinuria, remains a key program. Enrollment in the pivotal Phase III HARMONY study is continuing, with top-line results anticipated in the second half of 2027. Management highlighted the significant unmet need in the HCU community and the excitement surrounding pegtibatinase's potential to reduce total homocysteine and overcome current treatment limitations.

Travere recently closed an exclusive licensing agreement with Everest Medicines for civorebrutinib, an investigational oral BTK inhibitor. This addition strategically complements Travere's rare kidney disease portfolio, offering a distinct immune-mediated mechanism. The next step involves opening an IND in the U.S. and engaging with the FDA to define global clinical development pathways for multiple immune-mediated kidney diseases, including primary membranous nephropathy, immune-mediated FSGS, and minimal change disease.

The company presented long-term DUPLEX open-label extension data at ERA in June, demonstrating sustained proteinuria reductions for up to 5 years with no new safety signals for FILSPARI. Enrollment has been completed for a post-transplant study evaluating recurrent FSGS and IgA nephropathy, with data expected in 2027. Additionally, a Phase IV open-label study is planned for initiation in the second half of 2026 to further evaluate FILSPARI's efficacy and safety in adult and pediatric patients of African ancestry with FSGS.

Travere generated $161.4 million in total U.S. net product sales and $169.6 million in total revenue for Q2 FY26. GAAP R&D and SG&A expenses totaled $156.4 million, including $22.2 million in noncash stock-based compensation and depreciation. The company strengthened its balance sheet through a convertible note refinancing, repurchasing $221 million of 2029 notes and issuing $525 million of 2032 notes, resulting in $489.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026. An upfront payment of $112.5 million for civorebrutinib was made in July.